2. Search Result
Search Result
Results for "

bowel Disease

" in MedChemExpress (MCE) Product Catalog:

116

Inhibitors & Agonists

2

Screening Libraries

11

Peptides

4

Inhibitory Antibodies

8

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137789
    Tazofelone

    LY 213829

    		 COX Cancer
    Tazofelone (LY 213829) is a cyclooxygenase-II (COX-II) inhibitor. Tazofelone transform into sulfoxide and quinol metabolites is primarily mediated by CYP3A. Tazofelone can be used for the research of inflammatory bowel disease .
    Tazofelone
  • HY-16640
    TCJL37

    		JAK Inflammation/Immunology
    TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a Ki of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .
    TCJL37
  • HY-115744
    Mercaptoethylguanidine (MEG) (dihydrobromide)

    		NO Synthase Inflammation/Immunology
    Mercaptoethylguanidine (MEG) dihydrobromide is selective inhibitor of the inducible nitric oxide synthase and peroxynitrite scavenger. Mercaptoethylguanidine (MEG) dihydrobromide has the potential for inflammatory bowel diseases research.
    Mercaptoethylguanidine (MEG) (dihydrobromide)
  • HY-107015A
    Prednisolone metazoate sodium

    Predfoam; ATL 2502

    		 Others Inflammation/Immunology
    Prednisolone metazoate sodium (ATL 2502) can be used for study of inflammatory bowel disease, ulcerative colitis, and GI disorders .
    Prednisolone metazoate sodium
  • HY-158404
    METTL3-IN-8

    		METTL3 Inflammation/Immunology
    METTL3-IN-8 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates DSS-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research .
    METTL3-IN-8
  • HY-142834
    RORγt/DHODH-IN-2

    		ROR Dihydroorotate Dehydrogenase Inflammation/Immunology
    RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .
    RORγt/DHODH-IN-2
  • HY-118795
    SC-22716

    		Aminopeptidase Inflammation/Immunology
    SC-22716 is a potent, competitive, reversible inhibitor of human LTA4 hydrolase, with an IC50 of 0.20 µM. SC-22716 has potential for the research of inflammatory bowel disease (IBD) and psoriasis .
    SC-22716
  • HY-147527
    CDK8-IN-5

    		CDK Inflammation/Immunology
    CDK8-IN-5 is a potent CDK8 inhibitor with an IC50 of 72 nM. CDK8-IN-5 shows anti-inflammatory activities with 43% IL-10 enhancement rate. CDK8-IN-5 has the potential for the research of inflammatory bowel disease .
    CDK8-IN-5
  • HY-158403
    METTL3-IN-7

    		METTL3 Inflammation/Immunology
    METTL3-IN-7 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates dextran sodium sulfate (DSS)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research .
    METTL3-IN-7
  • HY-151952
    NLRP3-IN-12

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-12 is a specific NLRP3 inflammasome inhibitor. NLRP3-IN-12 reduces the release of IL-1β by targeting the NLRP3 protein, with an IC50 of 0.45 μM. NLRP3-IN-12 can be used for the research of inflammatory bowel disease .
    NLRP3-IN-12
  • HY-E70288
    ST6 Sialyltransferase 6

    ST6GALNAC6

    		 Others Inflammation/Immunology
    ST6 Sialyltransferase 6 (ST6GALNAC6) belongs to the salivary transferase family, which modifies proteins and ceramides on the cell surface, thereby altering intercellular or extracellular matrix interactions. ST6 Sialyltransferase 6 can be used in the study of inflammatory bowel disease (IBD) .
    ST6 Sialyltransferase 6
  • HY-168591
    CTSC-IN-1

    		Cathepsin Cancer
    CTSC-IN-1 (B22) is a CTSC inhibitor. CTSC-IN-1 inhibits CTSC activity by binding to S2 pocket and S1 site. CTSC-IN-1 can be used in the study inflammatory bowel disease .
    CTSC-IN-1
  • HY-12820
    Sibofimloc
    1 Publications Verification

    Antibiotic-202

    		 Bacterial Antibiotic Infection
    Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .
    Sibofimloc
  • HY-19667A
    BMS-561392 formate

    DPC 333 formate

    		 TNF Receptor Inflammation/Immunology
    BMS-561392 formate is the formate form of BMS-561392 (HY-19667). BMS-561392 is a TNF alpha-converting enzyme (TACE) inhibitor. BMS-561392 is also an ADAM17 blocker. BMS-561392 can be used for research of inflammatory bowel disease .
    BMS-561392 formate
  • HY-100278
    AKP-001

    		p38 MAPK Inflammation/Immunology
    AKP-001 is an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). AKP-001 can inhibit the production of inflammatory cytokines and can be used for research in rheumatoid arthritis and inflammatory bowel disease .
    AKP-001
  • HY-15707
    NS6180
    1 Publications Verification

    		 Potassium Channel Inflammation/Immunology
    NS6180 is a new orally active KCa3.1 channel inhibitor. NS6180 inhibits cloned human KCa3.1 channels with an IC50value of 9 nM. NS6180 can be used for the research of inflammatory bowel disease (IBD) .
    NS6180
  • HY-P3499
    Dolcanatide

    		Guanylate Cyclase Inflammation/Immunology
    Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .
    Dolcanatide
  • HY-N2549
    (±)-Abscisic acid

    (±)-ABA

    		 Calcium Channel Metabolic Disease Inflammation/Immunology
    (±)-Abscisic acid ((±)-ABA) is an orally active phytohormone. (±)-Abscisic acid induces Ca 2+ channel opening to facilitate the influx of calcium ions and modulates stomatal movement. (±)-Abscisic acid shows anti-inflammatory activity and has the potential for the research of inflammatory bowel disease (IBD) .
    (±)-Abscisic acid
  • HY-161757
    Anti-inflammatory agent 86

    		Others Inflammation/Immunology
    Anti-inflammatory agent 86 is a Chrysin (HY-14589) derivative with anti-inflammatory effects. Anti-inflammatory agent 86 inhibits monocyte adhesion to colon epithelium induced by TNF-α, with an IC50 of 4.71 μM. Anti-inflammatory agent 86 has the potential for the inflammatory bowel disease (IBD) research .
    Anti-inflammatory agent 86
  • HY-161735
    CXCR4-IN-3

    		CXCR Inflammation/Immunology
    CXCR4-IN-3 (compound XVI) is an orally active and potent inhibitor targeting the inflammation-related receptor CXCR4, with an IC50 of 3.2 nM. CXCR4-IN-3 exhibits potent antichemotactic activity, at 79.19±2.33% inhibition. CXCR4-IN-3 shows anti-inflammatory activity. CXCR4-IN-3 can be used for IBD (inflammatory bowel disease) research .
    CXCR4-IN-3
  • HY-P3507
    Dalazatide

    ShK-186

    		 Potassium Channel Metabolic Disease Inflammation/Immunology
    Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .
    Dalazatide
  • HY-151174
    PDE4-IN-12

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC50s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .
    PDE4-IN-12
  • HY-155680
    BET BD2-IN-1

    		Epigenetic Reader Domain Inflammation/Immunology
    BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC50=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research .
    BET BD2-IN-1
  • HY-163498
    NLRP3-IN-37

    		NOD-like Receptor (NLR) Neurological Disease Inflammation/Immunology
    NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury .
    NLRP3-IN-37
  • HY-P99184
    Abrilumab

    		Integrin Infection Inflammation/Immunology Cancer
    Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
    Abrilumab
  • HY-P3507A
    Dalazatide TFA

    ShK-186 TFA

    		 Potassium Channel Metabolic Disease Inflammation/Immunology
    Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .
    Dalazatide TFA
  • HY-P99486
    Briakinumab

    ABT-874

    		 Interleukin Related Inflammation/Immunology
    Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
    Briakinumab
  • HY-162734
    BRD5075

    		Interleukin Related Inflammation/Immunology
    BRD5075 is a potent GPR65 activator. BRD5075 induces GPR65-dependent cAMP production. BRD5075 decreases the gene expression of IL-1, IL-2, TNF, and chemokine. BRD5075 has the potential for the research of multiple sclerosis and inflammatory bowel disease (IBD) .
    BRD5075
  • HY-44809
    Izilendustat

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease Inflammation/Immunology
    Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1) .
    Izilendustat
  • HY-115497
    BRD5529

    		E1/E2/E3 Enzyme Infection Inflammation/Immunology
    BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) .
    BRD5529
  • HY-155199
    PDE1-IN-5

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor (IC50: 15 nM). PDE1-IN-5 has anti- inflammatory activity, and inhibits expression of iNOS, TNF-α, IL-1α, IL-1β, and IL-6 induced by LPS. PDE1-IN-5 has anti-inflammatory bowel disease (IBD) effects in the dextran sodium sulfate (DSS)-Induced colitis mice model. PDE1-IN-5 can be used for research of IBD .
    PDE1-IN-5
  • HY-14908
    Vidofludimus
    4 Publications Verification

    4sc-101; SC12267

    		 Dihydroorotate Dehydrogenase Interleukin Related FXR Infection Inflammation/Immunology
    Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .
    Vidofludimus
  • HY-P9984
    Etrolizumab
    1 Publications Verification

    rhuMAb Beta7; RG7413; PRO145223

    		 Integrin Cancer
    Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
    Etrolizumab
  • HY-P10587
    Icotrokinra

    JNJ-77242113; JNJ-2113; PN-235

    		 Interleukin Related STAT Inflammation/Immunology
    Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
    Icotrokinra
  • HY-14908A
    Vidofludimus hemicalcium

    4sc-101 hemicalcium; SC12267 hemicalcium

    		 Dihydroorotate Dehydrogenase Interleukin Related FXR Infection Inflammation/Immunology
    Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .
    Vidofludimus hemicalcium
  • HY-136233
    PSB 0777 ammonium

    		Adenosine Receptor Inflammation/Immunology
    PSB 0777 ammonium is a potent and selective adenosine A2A receptor full agonist with Ki values of 44.4 nM, 360 nM for rat and human A2A receptors, respectively. PSB 0777 ammonium has Ki values of ≥10000 nM, 541 nM for rat and human A1 receptors, respectively. PSB 0777 ammonium shows poor brain penetrant and perorally non-absorbable effect. PSB 0777 ammonium has the potential for inflammatory bowel disease (IBS) research research .
    PSB 0777 ammonium
  • HY-136233A
    PSB 0777 ammonium hydrate

    		Adenosine Receptor Inflammation/Immunology
    PSB 0777 ammonium hydrate is a potent and selective adenosine A2A receptor full agonist with Ki values of 44.4 nM, 360 nM for rat and human A2A receptors, respectively. PSB 0777 ammonium hydrate has Ki values of ≥10000 nM, 541 nM for rat and human A1 receptors, respectively. PSB 0777 ammonium hydrate shows poor brain penetrant and perorally non-absorbable effect. PSB 0777 ammonium hydrate has the potential for inflammatory bowel disease (IBS) research research .
    PSB 0777 ammonium hydrate
  • HY-109182
    Lorpucitinib

    JNJ-64251330

    		 JAK Inflammation/Immunology
    Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease .
    Lorpucitinib
  • HY-160477
    DC-SX029

    		PIKfyve NF-κB IKK Inflammation/Immunology
    DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with an estimated KD constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .
    DC-SX029
  • HY-B0174
    Olsalazine Disodium

    		Leukotriene Receptor Antibiotic Inflammation/Immunology
    Olsalazine Disodium is an anti-inflammatory compound that works in inflammatory bowel disease and ulcerative colitis.
    Olsalazine Disodium
  • HY-105092
    Tetomilast

    OPC-6535

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).
    Tetomilast
  • HY-107831
    5-Acetylsalicylic acid
    1 Publications Verification

    		 Others Inflammation/Immunology
    5-Acetylsalicylic acid has anti-inflammatory and is considered to be the active agent in inflammatory bowel disease (IBD) .
    5-Acetylsalicylic acid
  • HY-105534
    TAK-637

    		Neurokinin Receptor Neurological Disease
    TAK-637 is an orally active neurokinin-1 receptor antagonist. TAK-637 increases bladder storage capacity. TAK-637 can be used for research of functional bowel diseases such as irritable bowel syndrome .
    TAK-637
  • HY-107456
    E6130
    2 Publications Verification

    		 CX3CR1 Inflammation/Immunology Endocrinology
    E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.
    E6130
  • HY-13545
    ABT-510

    		Apoptosis Inflammation/Immunology Cancer
    ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .
    ABT-510
  • HY-13545B
    ABT-510 acetate

    		Apoptosis Inflammation/Immunology Cancer
    ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .
    ABT-510 acetate
  • HY-151262
    JAK-IN-23

    		JAK STING NF-κB STAT Inflammation/Immunology
    JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC50 values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) .
    JAK-IN-23
  • HY-102040
    Hispidol
    1 Publications Verification

    (Z)-Hispidol

    		 TNF Receptor Inflammation/Immunology
    Hispidol ((Z)-Hispidol) is a potential therapeutic for inflammatory bowel disease; inhibits TNF-α induced adhesion of monocytes to colon epithelial cells with an IC50 of 0.50 µM.
    Hispidol
  • HY-167706
    Diethyl-Lodoxamide

    		Others Inflammation/Immunology
    Diethyl-Lodoxamide is a highly potent GPR35 agonist with potential to inhibit inflammatory bowel disease. Diethyl-Lodoxamide activates GPR35 in humans, mice and rats, showing similar EC50 values. Diethyl-Lodoxamide can alleviate the clinical symptoms of DSS-induced inflammatory bowel disease in mouse models, and the effect is better than the traditional drug 5-ASA. The pharmaceutical properties of Diethyl-Lodoxamide have been optimized to better meet the requirements of drug design .
    Diethyl-Lodoxamide
  • HY-116164
    A-79175

    		Lipoxygenase Inflammation/Immunology
    A-79175 is a potent 5-lipoxygenase inhibitor that inhibits leukotriene formation. A-79175 is promising for research of various allergic and inflammatory diseases including asthma, allergic rhinitis, rheumatoid arthritis and inflammatory bowel disease .
    A-79175

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: